购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • HDAC
    (3)
  • Apoptosis
    (2)
  • Epigenetic Reader Domain
    (1)
  • Histone Acetyltransferase
    (1)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (2)
  • 5日内发货
    (4)
  • 20日内发货
    (1)
  • 35日内发货
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "protein deacetylase hdac1"的结果
筛选
搜索结果
TargetMol产品目录中 "

protein deacetylase hdac1

"的结果
  • 抑制剂&激动剂
    5
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    1
    TargetMol | Recombinant_Protein
  • 检测抗体
    4
    TargetMol | Antibody_Products
  • Crebinostat
    T270831092061-61-4In house
    Crebinostat 是一种有效的组蛋白去乙酰化酶 (HDAC) 抑制剂,对 HDAC1、HDAC2、HDAC3 和 HDAC6 有抑制作用, IC50 分别为 0.7 nM、1.0 nM、2.0 nM 和 9.3 nM。Crebinostat 可增加在体外神经元的突触蛋白 1 斑点沿树突 (synapsin-1 punctae along dendrites) 的密度。Crebinostat 可调节染色质介导的神经可塑性,增强小鼠的记忆。Crebinostat 可诱导组蛋白 H3 和组蛋白 H4 乙酰化,并增强 cAMP 反应元件结合蛋白 (CREB) 靶基因 Egr1 的表达。
    • ¥ 1730
    In stock
    规格
    数量
  • tw9
    TW9
    T36103
    TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1It is selective for BD2 over BD1 in BRD4 (IC50= 0.72 μM) and for HDAC1 over HDAC2 (IC50= 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells. 1.Zhang, X., Zegar, T., Weiser, T., et al.Characterization of a dual BET HDAC inhibitor for treatment of pancreatic ductal adenocarcinomaInt. J. Cancer147(10)2847-2861(2020)
    • ¥ 852
    待询
    规格
    数量
  • Givinostat
    吉诺司他, ITF-2357, ITF2357
    T36629497833-27-9
    Givinostat(ITF-2357)是一种非选择性和口服活性的HDAC抑制剂,能够抑制STAT5磷酸化,对crlf2重排的BCP-ALL具有抗肿瘤活性并诱导凋亡。Givinostat具有抗炎活性,在endotoxin刺激的PBMCs中抑制TNF-α和IL-1β,还能够促进β细胞的存活,可用于糖尿病、急性淋巴细胞白血病和关节炎。
    • ¥ 315
    In stock
    规格
    数量
  • CAY17c
    T383812414373-11-6
    CAY17c is an inhibitor of bromodomain-containing protein 4 (BRD4; IC50= 0.71 μM), as well as class I histone deacetylases (HDACs; IC50s = 0.046, 0.058, 0.075, and 0.167 μM for HDAC1, -2, -3, and -8, respectively) and class IIb HDACs (IC50s = 0.073 and 0.923 μM for HDAC6 and HDAC10, respectively).1It is selective for these enzymes over BRD2, -3, and -T (IC50s = >20 μM for all), as well as over HDAC4, -5, -7, -9, and -11 (IC50s = >10 μM for all). CAY17c inhibits the proliferation of HCT116, SW620, and DLD-1 colorectal cancer cells (IC50s = 0.45, 1.78, and 2.11 μM, respectively), as well as induces apoptosis and autophagy in HCT116 cells. It reduces tumor growth in an HCT116 mouse xenograft model when administered at doses of 15 and 30 mg/kg. 1.Pan, Z., Li, X., Wang, Y., et al.Discovery of thieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as bromodomain-containing protein 4/histone deacetylase dual inhibitors induce autophagic cell death in colorectal carcinoma cellsJ. Med. Chem.63(7)3678-3700(2020)
    • ¥ 2330
    35日内发货
    规格
    数量
  • JMJD3/HDAC-IN-1
    T797132883046-06-6
    JMJD3 HDAC-IN-1 (compound A5b) 是靶向 JMJD3 和 HDAC1(IC50=16 nM)的双重抑制剂。它能够促进 H3K27 高甲基化和 H3K9 高乙酰化,并通过裂解 caspase-7 和 PARP 导致细胞凋亡。此外,JMJD3 HDAC-IN-1 对抑制癌细胞克隆形成、迁移和侵袭也表现出有效性。
    • ¥ 10600
    8-10周
    规格
    数量